Home
Mette Pernille Myklebust's picture

Mette Pernille Myklebust

Guest Researcher
  • E-mailmette.myklebust@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2022). Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer. Frontiers in Oncology. 1-12.
  • Show author(s) (2022). MicroRNAs in Differentiation of Embryoid Bodies and the Teratoma Subtype of Testicular Cancer. Cancer Genomics & Proteomics. 178-193.
  • Show author(s) (2022). Mapping Proteome Changes in Microsatellite Stable, Recurrent Colon Cancer Reveals a Significant Immune System Signature. Cancer Genomics & Proteomics. 130-144.
  • Show author(s) (2022). Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal Adenocarcinomas. Cancers. 1-15.
  • Show author(s) (2021). Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study. Scientific Reports.
  • Show author(s) (2020). Mismatch repair phenotype determines the implications of tumor grade and CDX2 expression in stage II-III colon cancer. Modern Pathology.
  • Show author(s) (2020). Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. Acta Oncologica. 1016-1023.
  • Show author(s) (2019). Quantitative PCR Measurement of miR-371a-3p and miR-372-p Is Influenced by Hemolysis. Frontiers in Genetics. 1-9.
  • Show author(s) (2018). A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer. Scientific Reports. 1-9.
  • Show author(s) (2017). Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. OncoTarget. 87837-87847.
  • Show author(s) (2016). LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer. Acta Oncologica. 1425-1433.
  • Show author(s) (2015). Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer. Acta Oncologica. 470-479.
  • Show author(s) (2015). CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer. Tumour Biology. 1-12.
  • Show author(s) (2012). Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. British Journal of Cancer. 1684-1691.
  • Show author(s) (2012). Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients. British Journal of Cancer. 756-762.
  • Show author(s) (2011). MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer. British Journal of Cancer. 1719-1725.
  • Show author(s) (2008). Gene expression reveals two distinct groups of anal carcinomas with clinical implications. British Journal of Cancer. 1264-1273.
Doctoral dissertation
  • Show author(s) (2012). Molecular markers of anal cancer and colorectal cancer. A study of microRNAs, desmosomal cadherins and cyclin D1 isoforms.

More information in national current research information system (CRIStin)